Providing Unprecedented Visibility into FDA Approval Pending Class III Devices

New York, May 18, 2006 – Revere Data, LLC, a fast-growing provider of independent research data and investment analytics, today announced a new Revere Report that identifies companies with expected FDA Approval of Premarket Approval (PMA) Applications in 2006 and 2007. Data from Revere’s patented classification system and proprietary medical device pipeline database is included to provide insights into each device’s market size potential and competitive dynamic.

The MedTech PMA Pipeline Monitor Report is designed to generate ideas for trading and investment opportunities in the MedTech (Medical Device) sector. The Report is available to current Revere subscribers (attached) and for sale on Revere’s website at www.reveredata.com/reports/store/report/pmapipe/200605.

“The MedTech sector, while historically receiving less media coverage and investor attention vs. the Biopharmaceutical sector, has achieved some significant milestones in recent years with breakthrough innovations like the drug-eluting stents, robotic surgical systems, and personalized medicine diagnostics,” noted Brian Hill, Director of Research for Revere. “This new report is intended to shed light on potentially high-impact MedTech events on the horizon, very much like what we provide with PDUFA dates in the FDA Approval Decisions Report.”

Specifically, the MedTech PMA Pipeline Monitor Report provides expected FDA Approval dates for Class III medical devices in the next 2 years, along with detail on each device candidate’s:

* tradenames and indications
* competitive landscape
* potential market size
* approval impact ranking

“The amount and rate of change in the MedTech sector is accelerating,” explained Hill, “and attempting to track and assess them without Revere would be hugely time-consuming.”

Companies profiled in the initial MedTech PMA Pipeline Monitor Report include Abbott Laboratories, Allergan, Medtronic, STAAR Surgical, Digene, Stryker, and Boston Scientific.

“This new report showcases our unique strength in applying Revere’s classification system to mapping the medical device pipelines of virtually all publicly traded Healthcare companies,” said Kevin O’Brien, Chief Executive Officer of Revere.

“Together with the FDA Approval Decisions Report, Revere now offers investors a complete solution to staying on top of all upcoming drug and Class III device approvals.”

Revere’s exclusive content on product and industry classification and on key business relationships is available both in datafeeds and in Revere’s own applications. Revere’s customers include sellside agency and proprietary traders, buyside traders, hedge fund managers, portfolio managers, equity analysts, and other professionals at leading financial institutions, along with competitive intelligence, business development, and strategy specialists at major corporations.


Revere Data, LLC, provides finance and business professionals with superior data and analytics for companies traded publicly on U.S. exchanges. The Revere Data approach is based on precise product and industry classification and identification of key business relationships. Revere Data’s datafeeds and its research and real-time trading applications feature unique content derived from Revere Data’s own independent research: the Revere Hierarchy™, a patented classification system that provides unmatched detail in specifying a company’s business activities and identifying exact competitors, and Revere Relationships™, a database mapping a company to its key competitors, customers, suppliers, and strategic partners. For more information, please visit www.reveredata.com.